Marshall Wace
BCAB icon

Marshall Wace’s BioAtla BCAB Stock Holding History

Marshall Wace’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$44.4K Sell
5,553
-12,279
-69% -$144K ﹤0.01% 2985
2025
Q4 		$508K Buy
+17,832
New +$699K ﹤0.01% 2228
2025
Q3 		– Sell
-1,617
Closed -$32.3K – 2892
2025
Q2 		$32.3K Sell
1,617
-110
-6% -$2.23K ﹤0.01% 2621
2025
Q1 		$30.2K Sell
1,727
-5,734
-77% -$123K ﹤0.01% 2553
2024
Q4 		$220K Sell
7,461
-1,269
-15% -$107K ﹤0.01% 2328
2024
Q3 		$768K Buy
+8,730
New +$732K ﹤0.01% 1760
2024
Q1 		– Sell
-908
Closed -$112K – 2434
2023
Q4 		$112K Buy
+908
New +$78.7K ﹤0.01% 2032
2023
Q2 		– Sell
-5,713
Closed -$766K – 2470
2023
Q1 		$766K Buy
5,713
+4,945
+644% +$891K ﹤0.01% 1929
2022
Q4 		$317K Buy
+768
New +$319K ﹤0.01% 2546
2022
Q3 		– Sell
-1,091
Closed -$156K – 3338
2022
Q2 		$156K Sell
1,091
-692
-39% -$110K ﹤0.01% 3215
2022
Q1 		$445K Buy
1,783
+1,160
+186% +$485K ﹤0.01% 2826
2021
Q4 		$611K Buy
+623
New +$797K ﹤0.01% 2699

Other funds holding BCAB

ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Marshall Wace's BCAB Position: Q1 2026 in Review

Marshall Wace reduced its BioAtla (BCAB) stake by 69% in Q1 2026, selling an estimated $144K and leaving 5,553 shares worth $44.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2985.

Marshall Wace first reported a position in BCAB in Q4 2021 and has held it in 12 quarters since. The position peaked at $768K in Q3 2024. 36 funds tracked by Wall St. Rank hold BCAB as of Q1 2026.

  • Marshall Wace held 5,553 shares of BioAtla worth $44.4K as of Q1 2026.
  • Marshall Wace sold 12,279 BioAtla shares in Q1 2026, an estimated $144K.
  • BioAtla made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #2985 holding.
  • Marshall Wace first reported a position in BioAtla in Q4 2021 and has held it in 12 quarters since.
  • Marshall Wace's BioAtla position peaked at $768K in Q3 2024.
  • 36 funds tracked by Wall St. Rank held BioAtla as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.